Proton pump inhibitors blood

Omeprazole (p. 167) can cause maximal inhibition of HCl secretion. Given orally in gastric juice-resistant capsules, it reaches parietal cells via the blood. In the acidic milieu of the mucosa, an active metabolite is formed and binds covalently to the ATP-driven proton pump (H+/K+ ATPase) that transports H+ in exchange for IC into the gastric juice. Lansoprazole and pantoprazole produce analogous effects. The proton pump inhibitors are first-line drugs for the treatment of gastroesophageal reflux disease. 

METHOTREXATE PROTON PUMP INHIBITORS -OMEPRAZOLE Likely t plasma concentration of methotrexate and t risk of toxic effects, e.g. blood dyscrasias, liver cirrhosis, pulmonary toxicity, renal toxicity Attributed to omeprazole decreasing the renal elimination of methotrexate Monitor clinically and biochemically for blood dyscrasias and liver, renal and pulmonary toxicity... 

SULPHONYLUREAS PROTON PUMP INHIBITORS Possible t efficacy and adverse effects of sulphonylurea, e.g. hypoglycaemia Possible t absorption Monitor capillary blood glucose more closely l dose may be required... 

Metabolism of diazepam This may be inhibited by the proton pump inhibitor omeprazole, leading to high concentrations of diazepam in the blood. 

---